Immunogenicity of a recombinant, yeast-derived, anti-hepatitis-B vaccine after alternative dosage and schedule vaccination in Pakistani children

Vaccine

Volumn 23, Issue 50, 2005, Pages 5792-5797

  Akram, Dure Samin ^a   Maqbool, Sajid ^b   Khan, Dure Shawar ^a   Jafri, Rafat ^a   Randhawa, Sajid ^b   Valenzuela Silva, Carmen ^c   Lopez Saura, Pedro ^c  

^a CIVIL HOSPITAL   (Pakistan)

^b CHILDREN S HOSPITAL   (Pakistan)

^c Center for Biological Research Cuba   (Cuba)

Author keywords

Hepatitis B vaccine; Immunogenicity; Reduced dose; Two dose

Indexed keywords

HEPATITIS B VACCINE;

AGE DISTRIBUTION; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EVALUATION; FEMALE; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS VIRUS; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; PAKISTAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; STANDARDIZATION;

ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B; HUMANS; INFANT; MALE; PAKISTAN; VACCINATION; VACCINES, SYNTHETIC; VIRAL HEPATITIS VACCINES; YEASTS;

EID: 27944491587     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.06.013     Document Type: Article

References (36)

1. M.A. Kane Worldwide epidemiology of hepatitis B Soz Paraventimed 43 Suppl. 1998 S24 S26
2. F. Andre Hepatitis B epidemiology in Asia, the Middle East, and Africa Vaccine 18 Suppl. 1 2000 S20 S22
3. B.A. Zajac, D.J. West, W.J. McAleer, and E.M. Scolnick Overview of clinical studies with hepatitis B vaccine made by recombinant DNA J Infect 13 Suppl. A 1986 39 45
4. F.E. Andre Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine Am J Med 87 Suppl. 3A 1989 14s 20s
5. W. Szmuness, C.E. Stevens, and E.J. Harley Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States N Engl J Med 303 1980 833 841
6. T. Coates, R. Wilson, G. Patrick, F. Andre, and V. Watson Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines Clin Ther 23 3 2001 392 403
7. P. Kar, P. Jandwani, and V. Khurana Seroconversion with rDNA hepatitis B vaccine of Cuban origin Indian J Gastroenterol 16 1997 161 165
8. E. Pentón, V. Muzio, and M. González-Griego The hepatitis B virus (HBV) infection and its prevention by recombinant DNA viral surface antigen (rec-HBsAg) vaccine Biotecnol Aplicada 11 1994 1 11
9. M. Diaz Gonzalez, A. Chiang Macia, and D. Diaz Acosta The immunogenicity of the Heberbiovac-HB vaccine in children Rev Cubana Med Trop 48 3 1996 195 198
10. A. Jain, U.S. Mathur, P. Jandwani, R.K. Gupta, V. Kumar, and P. Kar A multicentric evaluation of recombinant DNA hepatitis B vaccine of Cuban origin Trop Gastroenterol 21 1 2000 14 17
11. M. Diaz Gonzalez, O. Navia Molina, J.R. Bravo Gonzalez, P. Pedroso-Flaquet, and A. Urbino Lopez The reactogenicity of Heberbiovac-HB vaccine at different doses Rev Cubana Med Trop 47 1 1995 65 70
12. S. Singh, and D.R. Sharma Tolerability of a recombinant DNA hepatitis B vaccine. Results of Post-marketing surveillance J Commun Dis 31 1999 53 55
13. A.J. Zuckerman, and T.J. Harrison Hepatitis B virus chronic liver disease and hepatocellular carcinoma Post Grad Med J 63 Suppl. 2 1987 13 19
14. H. Froehlich, and D.J. West Compliance with hepatitis B virus vaccination in a high-risk population Ethn Dis 11 2001 548 553
15. P. Rendi-Wagner, M. Kundi, H. Stemberger, G. Wiedermann, H. Holzmann, M. Hofer, K. Wiesinger, and H. Kollaritsch Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience Vaccine 19 2001 2055 2060
16. G. Leroux-Roels, B. Abraham, M. Fourneau, N. De Clercq, and A. Safary A comparison of two commercial recombinant vaccines for hepatitis B in adolescents Vaccine 19 2000 937 942
17. J. Sokhey, D.C. Jain, A.K. Harit, and A.C. Dhariwal Moderate immunization coverage levels in East Delhi: implications for disease control programmes and introduction of new vaccines J Trop Pediatr 47 2001 199 203
18. H.P. Levaux, W.H. Schonfeld, J.M. Pellissier, W.M. Cassidy, S.K. Sheriff, and C. Fitzsimon Economic evaluation of a 2-dose hepatitis B vaccination regimen for adolescents Pediatrics 108 2001 317 325
19. W.M. Cassidy, B. Watson, V.A. Ioli, K. Williams, S. Bird, and D.J. West A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory Pediatrics 107 2001 626 631
20. National Advisory Committee on Immunization (NACI). Statement on alternate adolescent schedule for hepatitis B vaccine (ACS-5). Canada Communicable Disease Report, vol. 26 (ACS-5); 1 July 2000. p. 19.
21. E. Hardy, E. Martinez, D. Diago, R. Diaz, D. Gonzalez, and L. Herrera Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris J Biotechnol 77 2000 157 167
22. O. Juliao, A. González, and V. Ramírez Estudio de inmunogenicidad para dos vacunas recombinantes contra hepatitis B comparando dos esquemas Biomédica 11 1991 71 83
23. N. Haq, S.S. Hasnain, M. Umar, Z. Abbas, and C. Valenzuela-Silva Lopez-Saura immunogenicity of 10 and 20 μg hepatitis B vaccine in a two-dose schedule Vaccine 21 2003 3179 3185
24. M.J. Gonzalez-Griego, Z. Cinza, and A. Ortega A comparative study between different regimens for administering 2 doses of the Cuban anti-hepatitis B vaccine Rev Cubana Med Trop 50 3 1998 218 220
25. F. Shokri, and A. Jafarzadeh High seroprotection rate induced by low doses of a recombinant hepatitis B vaccine in healthy Iranian neonates Vaccine 19 2001 4544 4548
26. D.J. Weber, W.A. Rutala, G.P. Samsa, J.E. Santimaw, and S.M. Lemon Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine JAMA 254 1985 3187 3489
27. F.E. Shaw Jr., H.A. Guess, and J.M. Roets Effect of anatomic injection site, age, and smoking on the immune response to hepatitis B vaccination Vaccine 7 1989 425 430
28. P. Pedroso-Flaquet, L. Rodríguez-Lay, and M. Díaz- González Immunogenicity of a recombinant DNA yeast-derived hepatitis B vaccine at different doses in healthy young adults Infect Dis Rev 3 3 2001 138 142
29. S.C. Hardler, and H.S. Margolis Hepatitis B immunization-vaccine types, efficacy, and indications for immunization J.S. Remington MN. Swartz Current Clinical Topics in Infectious Diseases 1992 Blackwell Scientific Publications Boston 282 308
30. ® (B, MSD) J Infect Suppl 7 1993 95 104
31. S.S. Liao, R.C. Li, and H. Li Long-term efficacy of plasma-derived hepatitis B vaccine among Chinese children: a 12-year follow-up study World J Gastroenterol 5 2 1999 165 166
32. H.B. Liu, Z.D. Meng, and J.C. Ma A 12-year cohort study on the efficacy of plasma-derived hepatitis B vaccine in rural newborns World J Gastroenterol 6 2000 381 383
33. R.B. Wainwright, B.J. McMahon, and L.R. Bulkow Duration of immunogenicity and efficacy of hepatitis B vaccine in Yupik Eskimo population JAMA 261 1989 2362 2366
34. B. Watson, D.J. West, A. Chilkatowsky, S. Piercy, and V.A. Ioli Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine Vaccine 19 2001 3164 3168
35. H. Froehlich, and D.J. West Compliance with hepatitis B virus vaccination in a high-risk population Ethn Dis 11 2001 548 553
36. H.P. Levaux, W.H. Schonfeld, J.M. Pellissier, W.M. Cassidy, S.K. Sheriff, and C. Fitzsimon Economic evaluation of a 2-dose hepatitis B vaccination regimen for adolescents Pediatrics 108 2001 317 325